Amendments to the Claims

This listing of claims replaces all prior versions, and listings, of claims in the above-identified application:

1. (Original) A method of augmenting rejection of cells by a subject, the method comprising administering to the subject an effective amount of a pharmaceutical composition comprising a D isomer of an inhibitor of indoleamine-2,3-dioxygenase.

2. (Currently amended) The method of claim [[1]] 42 wherein the inhibitor of indoleamine-2,3-dioxygenase is selected from the group of 1-methyl-D-tryptophan, β-(3-benzofuranyl)-D-alanine, β-(3-benzo(b)thienyl)-D-alanine, and 6-nitro-D-tryptophan.

3. (Original) The method of claim 2 wherein the inhibitor of indoleamine-2,3-dioxygenase is 1-methyl-D-tryptophan.

4. (Original) The method of claim 1 wherein the cells are tumor cells.

5. (Original) The method of claim 4, wherein the tumor cells are a cancer selected from the group consisting of melanoma, colon cancer, pancreatic cancer, breast cancer, prostate cancer, lung cancer, leukemia, brain tumors, lymphoma, sarcoma, ovarian cancer and Kaposi's sarcoma.

6. (Currently amended) The method of claim [[1]] 42 further comprising administering one [[ore]] or more chemotherapeutic agents to the subject.

7. (Original) The method of claim 6 wherein at least one chemotherapeutic agent is selected from the group consisting of cyclophosphamide, methotrexate, fluorouracil, doxorubicin, vincristine, ifosfamide, cisplatin, gemcytabine, busulfan, ara-C, and combinations thereof.

8. (Currently amended) The method of claim [[1]] 42 wherein the pharmaceutical composition further comprises at least one chemotherapeutic agent.

9. The method of claim 8 wherein at least one chemotherapeutic agent is selected from the group consisting of cyclophosphamide, methotrexate, fluorouracil, doxorubicin, vincristine, ifosfamide, cisplatin, gemcytabine, busulfan, ara-C, and combinations thereof.

10. (Currently amended) The method of claim [[1]] 42 further comprising administering radiation therapy.

11-16. (Cancel)

17. (Currently amended) The method of claim [[1]] 42 wherein the pharmaceutical composition is administered in combination with a cytokine.

18. (Original) The method of claim 17 wherein the cytokine is granulocyte-macrophage colony stimulating factor (GM-CSF) or flt3-ligand.

19. (Currently amended) The method of claim [[1]] 42 wherein the pharmaceutical composition further comprises a cytokine.

20. (Currently amended) The method of claim [[1]] 42 wherein the pharmaceutical composition is administered in combination with a vaccine.

21. (Original) The method of claim 20, wherein the vaccine is a tumor vaccine.

22. (Original) The method of claim 21 wherein the tumor vaccine is a melanoma vaccine.

23. (Original) The method of claim 21 wherein the tumor vaccine comprises genetically modified tumor cells.

24. (Original) The method of claim 23 wherein the genetically modified tumor cells are transfected with granulocyte-macrophage stimulating factor (GM-CSF).

25. (Original) The method of claim 20 wherein the vaccine comprises one or more immunogenic peptides.

26. (Original) The method of claim 21 wherein the tumor vaccine comprises dendritic cells.

27. (Original) A method of stimulating an immune response comprising administering an effective amount of a pharmaceutical composition comprising a D isomer of an inhibitor of indoleamine-2,3-dioxygenase.

28-41. (Cancel)

42. (Original) A method of delaying the relapse or progression of a tumor in a subject, the method comprising administering an effective amount of a pharmaceutical composition comprising a D isomer of an inhibitor of indoleamine-2,3-dioxygenase.

43. (Original) A method of treating a subject suffering from a neoplastic condition, the method comprising administering to the subject an effective amount of a pharmaceutical composition comprising a D isomer of an inhibitor of indoleamine-2,3-dioxygenase.

44-47. (Cancel)